By Dr Holly Holliday

Journal articles

Pereira BA; Ritchie S; Chambers CR; Gordon KA; Magenau A; Murphy KJ; Nobis M; Tyma VM; Liew YF; Lucas MC; Naeini MM; Barkauskas DS; Chacon-Fajardo D; Howell AE; Parker AL; Warren SC; Reed DA; Lee V; Metcalf XL; Lee YK; O'Regan LP; Zhu J; Trpceski M; Fontaine ARM; Stoehr J; Rouet R; Lin X; Chitty JL; Porazinski S; Wu SZ; Filipe EC; Cadell AL; Holliday H; Yang J; Papanicolaou M; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Vennin C; Yin J; Dew AB; McMillan PJ; Goldstein LD; Deveson IW; Croucher DR; Samuel MS; Sim HW; Batten M; Chantrill L; Grimmond SM; Gill AJ; Samra J; Jeffry Evans TR; Sasaki T; Phan TG; Swarbrick A; Sansom OJ; Morton JP; Pajic M; Parker BL; Herrmann D; Cox TR; Timpson P, 2024, 'Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response', Science Advances, 10, http://dx.doi.org/10.1126/sciadv.adl1197

Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Guo X; Sanguino YC; Gopalakrishnan A; Ehteda A; Tsoli M; Ziegler DS, 2024, 'COMBINED EPIGENETIC THERAPY WITH FACT AND BET INHIBITORS REMODELS CHROMATIN AND DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, 26, http://dx.doi.org/10.1093/neuonc/noae064.077

Rayner BS; Samadder A; Holliday H; Chen Y; Nguyen H; Lee A; Liu J; Hayden E; Ogunmodede OS; Rye K-A; Tsoli M; Bertoldo JB; Ziegler DS, 2024, 'THE BIG AND SMALL OF PROTEIN POST-TRANSLATIONAL MODIFICATIONS: TARGETING SUMOYLATION AND CITRULLINATION IN DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, 26, http://dx.doi.org/10.1093/neuonc/noae064.069

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2024, 'Erratum: miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma (Molecular Therapy (2022) 30(3) (1119–1134), (S1525001622000041), (10.1016/j.ymthe.2022.01.004))', Molecular Therapy, 32, pp. 2031 - 2033, http://dx.doi.org/10.1016/j.ymthe.2024.05.008

Ross SE; Holliday H; Tsoli M; Ziegler DS; Dinger ME, 2024, 'Abstract B015: RNA N6-methyladenosine (m6A) as a therapeutic target in Diffuse Midline Glioma (DMG)', Cancer Research, 84, pp. B015 - B015, http://dx.doi.org/10.1158/1538-7445.brain23-b015

Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Sanguino YC; Gopalakrishnan A; Ehteda A; Rayner B; Tsoli M; Ziegler DS, 2024, 'Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG)', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.BRAIN23-B016

Glover HJ; Holliday H; Shparberg RA; Winkler D; Day M; Morris MB, 2023, 'Signalling pathway crosstalk stimulated by L-proline drives mouse embryonic stem cells to primitive-ectoderm-like cells', Development (Cambridge), 150, http://dx.doi.org/10.1242/dev.201704

Thai LM; O'Reilly L; Reibe-Pal S; Sue N; Holliday H; Small L; Schmitz-Peiffer C; Dhenni R; Wang-Wei Tsai V; Norris N; Yau B; Zhang X; Lee K; Yan C; Shi YC; Kebede MA; Brink R; Cooney GJ; Irvine KM; Breit SN; Phan TG; Swarbrick A; Biden TJ, 2023, 'β-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFβ receptor signaling', iScience, 26, http://dx.doi.org/10.1016/j.isci.2023.106477

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004

Hayden E; Holliday H; Lehmann R; Khan A; Tsoli M; Rayner BS; Ziegler DS, 2021, 'Therapeutic targets in diffuse midline gliomas—an emerging landscape', Cancers, 13, http://dx.doi.org/10.3390/cancers13246251

Holliday H; Khoury A; Swarbrick A, 2021, 'Chromatin immunoprecipitation of transcription factors and histone modifications in Comma-Dβ mammary epithelial cells', STAR Protocols, 2, http://dx.doi.org/10.1016/j.xpro.2021.100514

Holliday H; Roden D; Junankar S; Wu SZ; Baker LA; Krisp C; Chan CL; McFarland A; Skhinas JN; Cox TR; Pal B; Huntington ND; Ormandy CJ; Carroll JS; Visvader J; Molloy MP; Swarbrick A, 2021, 'Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB', iScience, 24, http://dx.doi.org/10.1016/j.isci.2021.102072

McEvoy CR; Holliday H; Thio N; Mitchell C; Choong DY; Yellapu B; Leong HS; Xu H; Lade S; Browning J; Takano EA; Byrne DJ; Gill AJ; Duong CP; Li J; Fellowes AP; Fox SB; Swarbrick A; Prall OWJ, 2021, 'A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors', Laboratory Investigation, 101, pp. 26 - 37, http://dx.doi.org/10.1038/s41374-020-00484-3

McEvoy CR; Holliday H; Thio N; Mitchell C; Choong DY; Yellapu B; Leong HS; Xu H; Lade S; Browning J; Takano EA; Byrne DJ; Gill AJ; Duong CP; Li J; Fellowes AP; Fox SB; Swarbrick A; Prall OWJ, 2021, 'A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors.', Lab Invest, 101, pp. 26 - 37, http://dx.doi.org/10.1038/s41374-020-00484-3

Wu SZ; Roden DL; Wang C; Holliday H; Harvey K; Cazet AS; Murphy KJ; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy JR; Junankar S; Chan CL; Lam CE; Hui MN; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O'Toole S; Cox TR; Timpson P; Lim E; Liu XS; Swarbrick A, 2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. embj2019104063, http://dx.doi.org/10.15252/embj.2019104063

Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R, 2020, 'Targeting the id1-kif11 axis in triple-negative breast cancer using combination therapy', Biomolecules, 10, pp. 1 - 15, http://dx.doi.org/10.3390/biom10091295

Teo WS; Holliday H; Karthikeyan N; Cazet AS; Roden DL; Harvey K; Konrad CV; Murali R; Varghese BA; Thankamony AP; Chan CL; McFarland A; Junankar S; Ye S; Yang J; Nikolic I; Shah JS; Baker LA; Millar EKA; Naylor MJ; Ormandy CJ; Lakhani SR; Kaplan W; Mellick AS; O'Toole SA; Swarbrick A; Nair R, 2020, 'Id Proteins Promote a Cancer Stem Cell Phenotype in Mouse Models of Triple Negative Breast Cancer via Negative Regulation of Robo1', Frontiers in Cell and Developmental Biology, 8, http://dx.doi.org/10.3389/fcell.2020.00552

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01306-6

Wu S; Roden D; Wang C; Holliday H; Harvey K; Cazet A; Murphy K; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy J; Junankar S; Chan C-L; Lam E; Hui M; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O’Toole S; Cox T; Timpson P; Lim E; Liu S; Swarbrick A, 2020, 'Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135327

Holliday H; Roden D; Junankar S; Wu S; Baker L; Krisp C; Chan C-L; McFarland A; Skhinas J; Cox T; Pal B; Huntington N; Ormandy C; Carroll J; Visvader J; Molloy M; Swarbrick A, 2020, 'Inhibitor of Differentiation 4 (ID4) represses myoepithelial differentiation of mammary stem cells through its interaction with HEB', , http://dx.doi.org/10.1101/2020.04.06.026963

Holliday H; Baker LA; Junankar SR; Clark SJ; Swarbrick A, 2018, 'Epigenomics of mammary gland development', Breast Cancer Research, 20, http://dx.doi.org/10.1186/s13058-018-1031-x

Baker L; Krisp C; Roden D; Holliday H; Wu S; Junankar S; Serandour A; Mohammed H; Nair R; Chan C-L; Yang J; Foreman N; Fitzpatrick B; Sankaranarayanan G; Law AMK; Ormandy C; Naylor M; McFarland A; Simpson P; Lakhani S; O'Toole S; Selinger C; Anderson L; Samimi G; Hacker N; Kaplan W; Carroll J; Molloy M; Swarbrick A, 2018, 'A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.', BIORXIV, http://dx.doi.org/10.1101/281196

Baker LA; Holliday H; Swarbrick A, 2016, 'ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer', Endocrine-Related Cancer, 23, pp. R381 - R392, http://dx.doi.org/10.1530/ERC-16-0196

Back to profile page